Zydus Launches Semaglutide Injection in India with Innovative Pen Device
Ahmedabad, 21 March, 2026 – Zydus Lifesciences Limited has launched Semaglutide Injection in India under the brand names SEMAGLYN™ , MASHEMA™ and ALTERME™ following patent expiry. The Drug Controller General of India (DCGI) previously approved the manufacturing and marketing of the injection for the treatment of Type 2 Diabetes Mellitus and Obesity.The company is introducing an innovative, reusable multi-dose pen device. This device allows clinicians and patients to conveniently select and administer different dose strengths from a single pen, improving adherence, enhancing convenience, and lowering the overall cost of therapy. Zydus’ Semaglutide injection will be available in a 15mg/3ml cartridge and will be manufactured at Zydus Biotech Park, Ahmedabad. The average monthly cost of treatment will be approximately Rs. 2,200.
According to the International Diabetes Federation, 8.9 crore adults in India are living with diabetes, representing 10.5 percent of the adult population. Obesity prevalence is also rapidly rising across age groups, with increases of 91 percent in women and 146 percent in men.
About Zydus Lifesciences Limited
Zydus Lifesciences Ltd. is an innovation-led global lifesciences company with over 29,000 employees worldwide. The company focuses on discovering, developing, manufacturing, and marketing healthcare therapies, with 1,500 scientists dedicated to research and development.
Reference:
1. Data on file, Permission to Manufacture Pharmaceutical Formulation of New Drug for Sale or for Distribution, CDSCO
2. Prevalence of Obesity in India, UNICEF India
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.